Your experts in CHO and HEK293.

Featured

Publication Announcement

We are happy to announce a second-generation, improved host cell line for AAV production and for stable gene expression in HEK293 cells.

A HEKExpress® clonally derived T-antigen-negative HEK cell line called HEKzeroT® has been generated with superior productivity, eliminating safety concerns when producing recombinant Adeno-Associated Viruses (rAAV) for clinical purposes. The cell line rapidly grows in chemically defined media and is scalable for large-scale production.

Stay tuned to get a copy of the official publication when it’s released by signing up for our newsletter.

Featured

Meet us at BIO US in Boston, USA

We’re delighted to share we’ll be attending the BIO US Conference in Boston, USA June 5-8!
Stop by booth #1743 to speak with our scientific experts,
Matthew Richardson and George Hong, to learn more about our CHO & HEK293 cell line development services.

Featured

Thanks for meeting us at Nidovirus Symposium in Montreux, Switzerland

We enjoyed meeting you at the Nidovirus Symposium in Montreux, Switzerland May 14-18th, 2023!
Feel free to continue to connect with our Director of R&D,
Paco Pino, and VP of Global Business Development, Joeri Kint.

Featured

Thanks for meeting us at PEGS in Boston, USA

We were delighted to meet you at the the BIO US Conference in Boston, USA June 5-8!
Feel free to continue to connect with our scientific experts,
Matthew Richardson and George Hong, to learn more about our CHO & HEK293 cell line development services.

Featured

Thanks for joining us at BPI EU in Amsterdam, NL

We enjoyed meeting you at the BPI EU Conference in Amsterdam, Netherlands May 9-12th, 2023! Our VP of Global Business Development, Joeri Kint, gave a talk. Stay tuned for the recorded version to come.

Our services

Expect great science. It’s in our DNA.

Our services in stable cell line development and recombinant protein manufacturing cover the value chain – from DNA construction and transfection to CHO and HEK process development, to large-scale protein production. Our cGMP compliant facility enables the generation of Master Cell Banks and Master Working Banks (MCB, MWB).

ExcellGene’s reliable process and exceptional CHO cell host are the result of over twenty years of innovation and fine-tuning. Here’s what you can expect.

 

High Titers

Up to 14 g/L, fully chemically defined process

 

Speedy timelines

From DNA to stable,
high-yield clone in 8 weeks

 

Diverse protein formats

mAbs, bispecifics, fusion proteins, biosimilars, virus surface proteins

 

 

Robust cells for scalable processes

100 L, 500 L, 2000 L, 10’000 L

Cell line development

Early on in our development of the CHOExpress® and HEKExpress® systems, we were able to identify highly stable and robust cell lines for transfection, production and scale-up. Because of this, we can now develop cell lines in less than 5 months.

cGMP master cell banking

We provide the highest standard of quality at our Swissmedic inspected facility. Our flexible cGMP plant allows banking of cell cultures for clients that use an immortalized cell line for protein production.

Rapid protein production

Get up to 200 mg of protein in 3 weeks and up to 20 g of protein in 2 months. Our proprietary transient gene expression CHOExpress® and HEKExpress® cells have been optimized for rapid growth, efficient DNA uptake, high protein expression and high density in suspension cultures (> 30 million cells/mL).

AAV production

15 AAV serotypes have been produced with our HEKExpress® host system in animal-component free media
at high yield using a simple, scalable transfection technology.  

Tox material production

Have you been limited by not having enough materials to properly design your pre-clinical studies in animals? ExcellGene will help you plan experiments without the worry of running short of materials. We can deliver up to 500 grams of drug substance from a single batch.

Our technologies

A uniquely science-driven CDMO

Since 2001, ExcellGene has developed proprietary technologies and know-how that are key for the delivery of its clients’ projects on a timely manner and with a high degree of customization.

About us

We serve biotech solutions worldwide

We’ve provided biologics and biotech solutions to hundreds of clients, including 6 of the top 10 pharmaceutical firms, biotech companies, contract research organizations and academic institutions.

  • Biotech 47% 47%
  • Big pharmaceutical 25% 25%
  • Academic 11% 11%
  • Other 18% 18%

Recents posts